Nuvaira is a privately held company headquartered in Minneapolis, Minn. The company has developed the Nuvaira Lung Denervation System to address chronic lung diseases by treating the overactive airway nerves with Targeted Lung Denervation (TLD). The Nuvaira Lung Denervation System is CE Mark approved. The Nuvaira Lung Denervation System is under clinical investigation and is not commercially available in the USA. Nuvaira and dNerva are registered trademarks of Nuvaira, Inc.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
02/12/19	$79,000,000	Venture	Advanced Technology Ventures Endeavour Vision Lightstone Ventures Morgenthaler Qiming Venture Partners Richard King Mellon Foundation Split Rock Partners U.S. Venture Partners Versant Ventures Vertex Venture Holdings Windham Venture Partners	undisclosed